Results 201 to 210 of about 321,312 (283)

Predictive value of MRD monitoring by BCR clonality in the ZUMA‐7 randomized clinical trial for CAR T therapy in r/r lymphoma

British Journal of Haematology, EarlyView.
Brodie Miles, Daqin Mao, Saran Vardhanabhuti, Davide Bedognetti, Simone Filosto, Rhine Shen   +5 more
wiley   +1 more source

TrkA abundance is increased in cutaneous nerves in bortezomib‐induced neuropathy

Brain Pathology, EarlyView.
Cutaneous nerves in bortezomib‐induced peripheral neuropathy (BIPN) show reduced nerve fiber density, increased TrkA expression, and enhanced dermal angiogenesis, highlighting a pathological switch in NGF/TrkA signaling that may contribute to nerve damage and pain. Abstract Tropomyosin receptor kinase A (TrkA), a high‐affinity receptor for nerve growth
Yuying Jin, Nadine Cebulla, Daniel Schirmer, Eva Runau, Leon Flamm, Calvin Terhorst, Laura Jähnel, Johanna Güse, Nicola Giordani, Annett Wieser, Julian Brennecke, Annemarie Sodmann, Martin Kortüm, Robert Blum, Claudia Sommer   +14 more
wiley   +1 more source

Bridging Perspectives: How Canadian Patients and Caregivers View Quality of Life in Multiple Myeloma Compared to Validated Instruments. [PDF]

Curr Oncol
Patenaude J, Légaré A, Dupont F, Colasurdo G, Elias M, Beauchemin C, Lachaine J.   +6 more
europepmc   +1 more source

An intracellular recombinant single‐chain variable antibody fragment as a new class of phosphodiesterase type 5 inhibitors

British Journal of Pharmacology, EarlyView.
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz, Sophie Sprenger, Olga Schweigert, Sanika Mohagaonkar, Matti Walsdorff, Tanja Zeller, Filip Berisha, Viacheslav O. Nikolaev, Sergei D. Rybalkin   +8 more
wiley   +1 more source

Dietary patterns among individuals with plasma cell disorders- opportunities for targeted interventions. [PDF]

Blood Cancer J
Traore K, Castro F, Derkach A, Gorshein E, Serrano E, Taneja A, Hurtado Martínez JA, Lesokhin AM, Sahagun Sanchez Aldana AM, Flores Pérez PA, Usmani SZ, Ahlstrom JM, Block T, Hydren JR, Thomson CA, Shah UA.   +15 more
europepmc   +1 more source

Protectin D1 and maresin 1 attenuate airway hyperreactivity induced by IL‐13 in human isolated small bronchi

British Journal of Pharmacology, EarlyView.
Background and Purpose Interleukin (IL)‐13 is implicated in airway hyperreactivity (AHR), a key feature of asthma. We explored the potential anti‐AHR activity of selected specialised pro‐resolving mediators (SPMs) in IL‐13‐induced AHR models, using human bronchial smooth muscle cells (BSMCs) and human isolated bronchi.
Willem Abma, Sven‐Erik Dahlén, Craig E. Wheelock, Mikael Adner, Mamdoh Al‐Amerie, Erik Sachs, Kasra Vali Jalali, Leonardo De Maria, Henric Olsson, Jesper Säfholm   +9 more
wiley   +1 more source

Symptom burden and palliative care in patients with hematologic malignancies: a single-center experience. [PDF]

Support Care Cancer
Holopainen A, Kuittinen T, Tyynelä-Korhonen K, Lamminmäki A.   +3 more
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series

Blood Cancer Journal
Murali Janakiram, Lawrence Liu, Scott Goldsmith, Azra Borogovac, Sarah Lee, Nitya Nathwani, Michael Rosenzweig, Firoozeh Sahebi, Myo Htut   +8 more
doaj   +1 more source

Daratumumab in the Treatment of Multiple Myeloma: Real World Evidence (2018-2024) at the a. Gemelli Polyclinic (Rome) and Comparison With Registration Studies. [PDF]

Hosp Pharm
Favia M, Sperandeo M, Cerbo LD, Sabia A, Musicco F, Za T, Campopiano R, Rossi E, Pani M, Tarantino D.   +9 more
europepmc   +1 more source